Literature DB >> 27900546

Validation of the Chinese version of functional assessment of anorexia-cachexia therapy (FAACT) scale for measuring quality of life in cancer patients with cachexia.

Ting Zhou1, Kaixiang Yang2, Sudip Thapa1, Qiang Fu1, Yongsheng Jiang1, Shiying Yu3.   

Abstract

PURPOSE: The assessment of quality of life (QOL) is an important part of cachexia management for cancer patients. Functional assessment of anorexia-cachexia therapy (FAACT), a specific QOL instrument for cachexia patients, has not been validated in Chinese population. The aim of this study was to validate the FAACT scale in Chinese cancer patients for its future use.
METHODS: Eligible cancer patients were included in our study. Patients' demographic and clinical characteristics were collected from the electronic medical records. Patients were asked to complete the Chinese version of FAACT scale and the MD Anderson symptom inventory (MDASI), and then the reliability and validity were analyzed.
RESULTS: A total of 285 patients were enrolled in our study, data of 241 patients were evaluated. Coefficients of Cronbach's alpha, test-retest and split-half analyses were all greater than 0.8, which indicated an excellent reliability for FAACT scale. In item-subscale correlation analysis and factor analysis, good construct validity for FAACT scale was found. The correlation between FAACT and MDASI interference subscale showed reasonable criterion-related validity, and for further clinical validation, the FAACT scale showed excellent discriminative validity for distinguishing patients in different cachexia status and in different performance status.
CONCLUSIONS: The Chinese version of FAACT scale has good reliability and validity and is suitable for measuring QOL of cachexia patients in Chinese population.

Entities:  

Keywords:  Cancer cachexia; Functional assessment of anorexia-cachexia therapy; MD Anderson symptom inventory; Quality of life; Questionnaire validity

Mesh:

Year:  2016        PMID: 27900546     DOI: 10.1007/s00520-016-3508-4

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  38 in total

1.  The Quality of Life Questionnaire Core 30 (QLQ-C30) and Functional Assessment of Cancer-General (FACT-G) differ in responsiveness, relative efficiency, and therefore required sample size.

Authors:  Madeleine T King; Melanie L Bell; Daniel Costa; Phyllis Butow; Byeongsang Oh
Journal:  J Clin Epidemiol       Date:  2013-10-11       Impact factor: 6.437

Review 2.  Cancer cachexia update in head and neck cancer: Definitions and diagnostic features.

Authors:  Marion E Couch; Kim Dittus; Michael J Toth; Monte S Willis; Denis C Guttridge; Jonathan R George; Christie A Barnes; Christine G Gourin; Hirak Der-Torossian
Journal:  Head Neck       Date:  2014-03-25       Impact factor: 3.147

3.  Re-validation and shortening of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire.

Authors:  J M Ribaudo; D Cella; E A Hahn; S R Lloyd; N S Tchekmedyian; J Von Roenn; W T Leslie
Journal:  Qual Life Res       Date:  2000       Impact factor: 4.147

4.  Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value.

Authors:  Drazena Srdic; Sanja Plestina; Ana Sverko-Peternac; Nora Nikolac; Ana-Maria Simundic; Miroslav Samarzija
Journal:  Support Care Cancer       Date:  2016-05-28       Impact factor: 3.603

5.  Variability and sample size requirements of quality-of-life measures: a randomized study of three major questionnaires.

Authors:  Yin-Bun Cheung; Cynthia Goh; Julian Thumboo; Kei-Siong Khoo; Joseph Wee
Journal:  J Clin Oncol       Date:  2005-08-01       Impact factor: 44.544

Review 6.  Cancer cachexia syndrome: pathogenesis, diagnosis, and new therapeutic options.

Authors:  Patrizia Mondello; Michael Mian; Carmela Aloisi; Fausto Famà; Stefania Mondello; Vincenzo Pitini
Journal:  Nutr Cancer       Date:  2014-12-16       Impact factor: 2.900

7.  Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group.

Authors:  Florian Strasser; Diana Luftner; Kurt Possinger; Gernot Ernst; Thomas Ruhstaller; Winfried Meissner; You-Dschun Ko; Martin Schnelle; Marcus Reif; Thomas Cerny
Journal:  J Clin Oncol       Date:  2006-07-20       Impact factor: 44.544

8.  Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment.

Authors:  Carla M M Prado; Vickie E Baracos; Linda J McCargar; Tony Reiman; Marina Mourtzakis; Katia Tonkin; John R Mackey; Sheryl Koski; Edith Pituskin; Michael B Sawyer
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

9.  Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Authors:  Se-Il Go; Mi Jung Park; Haa-Na Song; Hoon-Gu Kim; Myoung Hee Kang; Hyang Rae Lee; Yire Kim; Rock Bum Kim; Soon Il Lee; Gyeong-Won Lee
Journal:  J Cachexia Sarcopenia Muscle       Date:  2016-04-12       Impact factor: 12.910

10.  Development and validation of quality of life scale of nasopharyngeal carcinoma patients: the QOL-NPC (version 2).

Authors:  Yong Su; Chuan-Wei Mo; Wan-Qin Cheng; Lei Wang; Qian Xu; Zu-Chun Wu; Zhe-Li Wu; Li-Zhi Liu; Xin-Lin Chen
Journal:  Health Qual Life Outcomes       Date:  2016-05-10       Impact factor: 3.186

View more
  2 in total

1.  Study on the relationship between sarcopenia and its components and anorexia in elderly maintenance haemodialysis patients.

Authors:  Chao Li; Lin Chen; Li He; Yingjun Zhang; Hui Chen; Yuan Liu; Sikai Tang; Haotian Zheng
Journal:  Nurs Open       Date:  2021-12-14

2.  Development and validation of a clinically applicable score to classify cachexia stages in advanced cancer patients.

Authors:  Ting Zhou; Bangyan Wang; Huiquan Liu; Kaixiang Yang; Sudip Thapa; Haowen Zhang; Lu Li; Shiying Yu
Journal:  J Cachexia Sarcopenia Muscle       Date:  2018-01-25       Impact factor: 12.910

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.